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Abstract After endothelial injury, the transcription factor
Kru¨ppel-like factor 6 (KLF6) translocates into the cell
nucleus to regulate a variety of target genes involved in
angiogenesis, vascular repair and remodeling, including
components of the membrane transforming growth factor
beta (TGF-b) receptor complex such as endoglin and
activin receptor-like kinase 1. The membrane metallopro-
teinase 14 (MMP14 or MT1-MMP) targets endoglin to
release soluble endoglin and is involved in vascular
inflammation and endothelial tubulogenesis. However, lit-
tle is known about the regulation of MMP14 expression
during vascular wounding. In vitro denudation of mono-
layers of human endothelial cell monolayers leads to an
increase in the KLF6 gene transcriptional rate, followed by
an upregulation of MMP14 and release of soluble endoglin.
Concomitant with this process, MMP14 co-localizes with
endoglin in the sprouting endothelial cells surrounding the
wound border. MMP14 expression at mRNA and protein
levels is increased by ectopic KLF6 and downregulated by
KLF6 suppression in cultured endothelial cells. Moreover,
after wire-induced endothelial denudation, Klf6?/- mice
show lower levels of MMP14 in their vasculature com-
pared with their wild-type siblings. Ectopic cellular
expression of KLF6 results in an increased transcription
rate of MMP14, and chromatin immunoprecipitation assays
show that KLF6 interacts with MMP14 promoter in ECs,
this interaction being enhanced during wound healing.
Furthermore, KLF6 markedly increases the transcriptional
activity of different reporter constructs of MMP14 gene
promoter. These results suggest that KLF6 regulates
MMP14 transcription and is a critical player of the gene
expression network triggered during endothelial repair.
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Introduction
The endothelium plays a crucial role in regulating patho-
physiological processes like vascular injury, angiogenesis,
vascular remodeling, tumor growth, vasoconstriction,
vasodilatation, inflammation or blood vessel permeability.
During all these processes, proliferation, migration and
invasion of endothelial cells (ECs) are essential and the
study of the regulatory mechanisms involved in endothelial
gene expression is a necessary step in the search of ther-
apeutic targets.
Electronic supplementary material The online version of this
article (doi:10.1007/s10456-016-9495-8) contains supplementary
material, which is available to authorized users.
& Carmelo Bernabeu
bernabeu.c@cib.csic.es
1 Centro de Investigaciones Biolo´gicas, CSIC, c/Ramiro de
Maeztu 9, Madrid 28040, Spain
2 Centro de Investigacio´n Biome´dica en Red de Enfermedades
Raras (CIBERER), Madrid 28040, Spain
3 Servei de Cardiologia, Hospital Clı´nic i Institut
d’Investigacions Biome`diques August Pi i Sunyer, Barcelona,
Spain
4 Division of Liver Diseases, Icahn School of Medicine at
Mount Sinai, New York, NY, USA
5 Department of Cardiovascular Sciences, University of
Leicester, Leicester, UK
6 National Institute for Health Research, Leicester





Upon vascular injury, a coordinated gene expression
program is triggered among those genes coding for extra-
cellular matrix proteins, growth factors, receptors and
proteases. One of these classes of proteins is the trans-
forming growth factor-b (TGF-b) family, which includes
TGF-b, activins and bone morphogenetic proteins (BMPs).
TGF-bs are angiogenic factors that target ECs during
vascular wound healing and signal through the Smad
family of transcription factors [1]. Mutations in endothelial
components of the TGF-b system are responsible for sev-
eral inherited vascular diseases [2]. Thus, heterozygous for
mutations in the ENG (endoglin), ACVRL1 (activin
receptor-like kinase 1; ALK1), GDF2 (BMP9) or SMAD4
genes results in different variants of the familial vascular
disorder known as hereditary hemorrhagic telangiectasia
(HHT) characterized by an abnormal angiogenesis process
where boundaries between arteries and veins are not well
established [3, 4]. Endoglin protein is a membrane TGF-b
co-receptor expressed primarily in ECs to regulate TGF-b
signaling in the cardiovasculature [5, 6]. Endoglin is
essential for angiogenesis during development, required for
the maintenance of a normal vasculature in the adult, and
mice that are homozygous for mutations in Eng die in mid-
gestation from vascular defects [7–9].
The matrix metalloproteases (MMPs) represent an
important family of proteins involved in diverse biological
processes, including angiogenesis, stroke, vascular repair,
inflammation and cancer [10–13]. Sustained MMP activity
is associated with vascular pathologies such as hyperten-
sion, restenosis, vascular malformations and atherosclero-
sis [14, 15]. During angiogenesis, MMPs play a key role in
extracellular matrix degradation, favouring endothelial cell
migration and vascular invasion. Among these, MMP14 is
a membrane-type MMP (MT-MMP) belonging to the col-
lagenase type I class. In the vascular setting, MMP14 is
involved in: (i) capillary tube formation of human ECs
using 3D collagen matrices [10, 16]; (ii) the inflammatory
response of ECs [17]; (iii) the atherosclerotic plaque vul-
nerability [18–20]; and (iv) the cross-talk between human
airway basal cells and ECs [21]. Interestingly, MMP14 is
upregulated in wound-derived blood vessels compared with
vessels from intact human skin [22]. In addition to
degrading the collagen surrounding new vascular cells
[23], MMP14 releases latent TGF-b1 from latent TGF-
binding protein (LTBP) and activates other MMPs secreted
to the medium, such as MMP2, which has a critical role
downstream of MMP14 for angiogenesis-mediated tumor
invasion [24]. An increased number of MMP14 proteolytic
substrates have been described recently, as well as its
adhesive role in binding to collagens, glycoproteins, pro-
teoglycans, integrins, cadherins and CD44 [17, 24]. In ECs,
membrane endoglin is a proteolytic substrate of MMP14
resulting in the release of soluble endoglin [25, 26], which
is associated with systemic hypertension during pregnancy
and contributes to the pathogenesis of preeclampsia
[26–29]. Soluble endoglin antagonizes the functions of its
membrane-bound form by inhibiting angiogenesis, capil-
lary tube formation and sprouting, and increasing vascular
permeability [25, 27, 30]. However, little is known about
the putative release of soluble endoglin during endothelial
injury and how MMP14 gene expression is activated to
cleave membrane endoglin.
The zinc finger Kru¨ppel-like factor (KLF) family of
transcription factors regulates diverse biological processes
including proliferation, development, survival and respon-
ses to external stress [31, 32]. Several studies support an
important role for this family of factors in vascular biology
[33]. KLF6 is considered as a damage-response factor that
promotes vascular remodeling because of its ability of
transactivating several endothelial target genes by direct
binding to their promoters [31]. Upon vascular injury,
KLF6 expression increases and translocates into the
nucleus to specifically enhance the transcriptional activity
of endoglin and activin receptor-like kinase 1 (ALK1)
[34, 35]; two key TGF-b receptors involved in vascular
remodeling and angiogenesis [36]. KLF6 also targets a
pool of genes involved in motility and invasion during
vascular remodeling and angiogenesis including collagen
a1 [37], E-cadherin, MMP9, tissue factor pathway inhi-
bitor-2 (TFPI-2), urokinase plasminogen activator, IL6 and
VEGF [31, 33, 34, 38]. Furthermore, KLF6 knock-out mice
are embryonic lethal due to a failure of erythropoiesis and
yolk sac vascularization [39]. Altogether, these data point
to KLF6 as a key regulator of angiogenesis and vascular
remodeling.
Here, we have addressed whether gene expression of
MMP14 and its proteolytic activity on its substrate endo-
glin are deregulated upon vascular injury. We have also
investigated the possible involvement of the transcription
factor KLF6 during this process. Our results demonstrate
that on vascular injury, KLF6 transcriptionally upregulates
the expression of MMP14 that is associated with increased
MMP14 proteolytic activity leading to the release of sol-
uble endoglin from ECs.
Materials and methods
Cell culture
The primary culture of human umbilical vein-derived
endothelial cells (HUVEC) was obtained from Lonza.
These cells were cultured in early passages (3–10) and
exponentially grown onto 0.2 % gelatin (Sigma) pre-coated
plates in endothelial basic medium (EBM2) supplemented
with endothelial growth medium (EGM2; Lonza). The
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human embryonic kidney (HEK293T) cell line was cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco). Both cell types were cultured at 37 C in 5 % CO2.
All the media were supplemented with 10 % heat inacti-
vated fetal bovine serum (FBS; Gibco), 2 mM L-glutamine,
100 U/mL penicillin and 100 lg/mL streptomycin (Gibco).
Endothelial wound healing assay
For wound healing assays, cells were grown to confluence
onto 0.2 % gelatin pre-coated wells. The wound was cre-
ated by scratching the cell monolayer using a sterile pipette
tip. Then, plates were immediately washed twice with PBS
to remove the remaining cells and fresh medium was
added. Endothelial cell migration into the denuded area
was monitored with photographs taken at the time of the
wound (0 h) and 2, 4, 6, 8 and 24-h post-wound. The Image
J program was used to quantify the wound healing process
by measuring the distance between the edges of the
denuded area.
Mice and mechanical injury experiments
Generation of Klf6?/- mice in the C57BL/6 strain has been
previously reported [39]. To monitor the expression pattern
of MMP14 in a vascular injury, we followed the technique
described by Garrido et al. [34]. Briefly, Klf6?/? and
Klf6?/- mice were anesthetized and underwent bilateral
endoluminal injury to the common femoral artery by
passing three times a 0.25-mm-diameter angioplasty
guidewire as described [40]. At 28 days post-injury, mice
were killed and approximately 2-mm-thick transverse
segments were cut at the level of the injury, in previously
isolated hind limbs blocks embedded in paraffin. Five-lm
cross-sections were obtained throughout the injured
fragment.
Inmunohistochemistry
Paraffin embedded sections of femoral arteries were pre-
warmed at 60 C and deparaffinized with xylene prior to
hydration with a series of ethanol-graded dilutions fol-
lowed by distilled water. Slides were subjected to antigen
retrieval with 0.01 M sodium citrate buffer, pH 6.0 for
45 min at 95 C in a water bath. The endogenous peroxi-
dase activity of the tissues and unspecific epitopes was
blocked with ‘‘peroxidase blocking reagent’’ during 5 min
and ‘‘protein blocking reagent’’ during 30 min, respec-
tively. All the reagents used were from NovoLink Polymer
Detection System Kit for IHC (Novocastra, Millipore).
MMP14 staining was detected with a rabbit monoclonal
anti-MMP14 antibody (ab51074, Abcam) incubated over-
night at 4 C. Then, samples were incubated with the
secondary antibody biotin-goat anti-rabbit IgG (H ? L),
followed by incubation with streptavidin–HRP (Cat
#21126; Pierce). For development of the peroxidase
activity, 3,30-diaminobenzidine (DAB) chromogen was
used. Nuclei were counterstained with Mayer’s hema-
toxylin 0.02 %, followed by immersion in ammonia water.
Finally, slides were mounted in HiMo (05-HM, Bio-Op-
tica, Milano, Italy) for observation with a camera-coupled
bright-field microscope.
ELISA of soluble endoglin and IL-6
HUVEC monolayers were scratched with a pipette tip as
described above. Culture supernatants were collected at the
indicated times and analyzed by ELISA assays. Concen-
trations of human soluble endoglin and human IL-6 in the
cell culture media were determined according to the
manufacturer protocol by Quantikine Human Endoglin/
CD105 and Quantikine Human IL-6, respectively
(DNDG00 and D6050; R&D Systems). Soluble endoglin
was also measured in the culture media of HUVECs or
HEK293T cells previously transfected with expression
vectors, as indicated. All immunoassays were measured in
a GloMax multidetection system (Promega) and normal-
ized by the percentage of cells in each control and post-
wounded well.
Inmunofluorescence microscopy
In order to monitor the co-localization of MMP14 and
endoglin in the membrane during the wound healing pro-
cess, HUVECs were grown to confluence onto 12-mm-
diameter coverslips, previously coated with 0.2 % (v/v)
gelatin (Sigma-Aldrich) in PBS. When necessary,
HUVECs were nucleofected with KLF6 plasmids and
siRNAs for 48 h, prior to the wound healing assay. Then,
the endothelial monolayer was disrupted once with a
micropipette tip. After 4 and 6 h, cells were fixed with 3 %
paraformaldehyde in PBS and blocked with PBS-BSA 1 %,
prior to the incubation with the primary antibody mouse
antihuman endoglin (P4A4; DHSB). Afterward, samples
were washed with PBS twice and incubated with the sec-
ond primary antibody, monoclonal rabbit antihuman
MMP14 (ab51074, Abcam). Then, cells were incubated
with two different secondary antibodies: Alexa 488 goat
anti-mouse IgG and/or Alexa 647 goat anti-rabbit IgG
(Molecular Probes, Invitrogen). To visualize the samples
and for nuclear staining, the slides were mounted in Pro-
long-DAPI reagent (Molecular Probes, Invitrogen). Sam-
ples were observed using a fluorescence confocal
microscopy Sp5 (DMI6000 CS Leica Microsystems). For
the semi-quantification of fluorescence intensity and co-
localization of endoglin and MMP14, an analysis of scatter
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plots (cytofluorograms) was carried out in the central layers
of each condition. Data about the distribution of fluores-
cence signals and specific overlapping pixels were obtained
taking into account Pearson’s correlation and setting a
common background and threshold for green and red
channels. All these measurements were obtained using the
Image J and LAS-AF 2.6 software.
In silico analysis of promoter sequences
In silico analysis of GC-boxes containing putative KLF6
and Sp1 motifs in the MMP14 proximal promoter, corre-
sponding to the upstream sequences of human (ID: 4323)
and mouse (ID: 17387) genes, was performed by the
Genomatix MatInspector software tool (http://www.geno
matix.de/products/MatInspector).
Flow cytometry
HUVECs were collected at different times (0, 2, 4, 6 and
8 h) after injury for the analysis of MMP14 and endoglin
expression levels at the endothelial cell surface. Cells were
incubated with a mouse monoclonal antibody against
human endoglin (CD105; P4A4) or a rabbit monoclonal
antibody against human MMP14 (ab51074, Abcam). A
negative control was included using an irrelevant isotype
control antibody X63 (IgG1). After washing the cells, they
were incubated with Alexa Fluor 488 goat anti-mouse (A-
11001 Molecular Probes, Invitrogen) for endoglin detec-
tion or Alexa Fluor 488 goat anti-rabbit IgG (11008
Molecular Probes, Invitrogen) for MMP14 detection. When
working with nucleofected HUVECs, the expression levels
of endoglin and MMP14 were measured by incubation with





















































































































































Fig. 1 MMP14 and endoglin mRNA levels increase in endothelial
cells after in vitro denudation. a HUVECs were wounded in vitro,
leaving approximately 40 % intact of total monolayer. Photographs
were taken at different times after wounding (0–8 h). Cells were lysed
at the times indicated (0–24 h), and RNA was extracted and processed
for qRT-PCR of human MMP14 and endoglin genes (b). KLF6, as a
primary response gene to injury, was also quantified (c). mRNA
expression levels of KLF6 (d), MMP14 (e) and endoglin (f) genes
were measured upon KLF6 suppression with siRNA specific for
KLF6 (siKLF6), using scrambled siRNA as a control. Fold change of
mRNA expression levels with respect to basal conditions are
indicated. Results were normalized to gene expression levels of 18S
rRNA, as a housekeeping gene that does not change during the wound
healing process. *p\ 0.05; **p\ 0.01; ***p\ 0.001 with respect to
basal conditions
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directly conjugated primary antibodies: Alexa Fluor 488
antihuman MMP14 (#128527; R&D Systems) and APC
anti-endoglin/CD105 (#166707; R&D Systems). The fluo-
rescence intensity was estimated with an EPICS XL and
FC 500 flow cytometers (Beckman Coulter). A minimum
of 10,000 cells were counted for each experimental point.
Metalloproteinase activity
Metalloproteinase activity of HUVECs was determined
using the fluorogenic peptide substrate Mca-PLGL-Dpa-
AR-NH2 (ES001; R&D Systems). HUVEC monolayers, at
control conditions and at different times after wounding,
were washed and incubated with 3 lM fluorogenic peptide
diluted in DMSO and TNC buffer (50 mM Tris, 0.15 M
NaCl, 10 mM CaCl2 and 0.002 % NaN3; pH, 7.5) during
1 h at 37 C. The reaction was stopped by adding stop
solution 10X (100 nM EDTA ? 0.02 % NaN3). The fluo-
rescence signal was read with a Varioskan flash spectral
scanning multimode reader (Thermo Scientific).
Quantitative real-time PCR
Total mRNA was isolated with the SpeedTools Total RNA
Extraction Kit (Biotools). A total of 1 lg of RNA was
retrotranscribed with a high capacity cDNA reverse tran-
scription kit (170-8891; iScript cDNA Synthesis kit;
BioRad). The resulting cDNA was used as a template for
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Time  (h)
0 4 6 
Time  (h)
0 4 6 
Fig. 2 MMP14 protein
expression and activity are
increased during wound healing.
MMP14 (a) and endoglin
(b) protein levels on the surface
of HUVECs at different time
points during wound healing
experiments were analyzed by
flow cytometry as described in
‘‘Materials and methods.’’
Histograms indicate protein
levels represented as fold
induction with respect to resting
cells at 8 h (control, C).
MMP14 (c) and endoglin
(d) protein levels on the surface
of HUVECs at different time
points after wound healing were
measured by flow cytometry
upon KLF6 suppression with
siRNA specific for KLF6
(siKLF6). Scrambled siRNA
(siScrambled) was used as a
control. Histograms indicate
protein levels represented as
fold induction with respect to
cells at 0 h. e MMP14 activity
was measured during
endothelial wound healing using
a fluorogenic peptide and
represented as a fold induction
with respect to cells at time 0 h.
f The percentage of endothelial
healing is represented at
different time points after
wounding. Cells at
approximately 80 % confluency
(6 h after wounding) showed
the highest MMP14 activity.
*p\ 0.05; **p\ 0.01;
***p\ 0.001 with respect to
control condition (a, b), to time
0 h (e), or as indicated (c, d)
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quantitative real-time PCR (qRT-PCR) performed using
LightCycler 480 PCR Master SYBR Green (Roche Applied
Biosciences). Oligonucleotides for selected genes were
designed using Roche software for qRT-PCR. The fol-
lowing forward (Fw) and reverse (Rv) primers were used:
hENG, Fw 50-GCCCCGAGAGGTGCTTCT-30 and Rv 50-
TGCAGGAAGACACTGCTGTTTAC-30; hKLF6, Fw 50-
CGGACGCACACAGGAGAAAA-30 and Rv 50-CGGTG
TGCTTTCGGAAGTG-30; hIL6, Fw 50-GAAGGCAG
CAGGCAACAC-30 and Rv 50-CAGGAGCCCAGCTAT
GAACT-30; hMMP14, Fw 50-CGATGTGGTGTTCCAG
ACAA-30 and Rv 50-TGGATGCAGAAAGTGATTTC-30.
As an internal control, mRNA levels of 18S were measured
using primers Fw 50-CTCAACACGGGAAACCTCAC-30
and Rv 50-CGCTCCACCAACTAAGAACG-30. Ampli-
cons were detected using a LightCycler 480 System II-384
(Roche Applied Biosciences). The specificity of the PCR
products was assessed by melting curve analyses which
showed only single amplified products. Assays were done
in triplicate, and the results were normalized according to
the expression levels of 18S rRNA.
Cell transfection, plasmids and reporter assays
Transient HEK293T transfections and HUVECs nucleo-
fections were carried out using Lipofectamine 2000 (In-
vitrogen) and Amaxa HUVEC Nucleofector kit (VPB-
1002, Lonza), respectively, according to the manufac-
turer’s instructions. Cells were analyzed 48 h later for
protein and mRNA expression by flow cytometry or qRT-
PCR. Human KLF6 was overexpressed by the encoding
vector pCiNeo/KLF6 [35]. The siRNA-mediated KLF6
knock-down was carried out using a pool of five siRNAs
targeting human KLF6 (sc-38021; Santa Cruz Biotech-
nology) and scrambled siRNA (Universal negative control
SIC001; Sigma), as a negative control. The pMax-GFP
vector (Amaxa Biosystems) was used as a control to assess
transfection efficiency. For MMP14-luciferase reporter
assays, three different 50-serial constructs (-1544/?235;
-800/?235; -300/?235) of the MMP14 promoter
(pMT1) were chemically synthesized and cloned (BioNova
Cientifica SL) into the pGL2-luc basic reporter plasmid
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Time
Fig. 3 MMP14 and endoglin co-localize upon endothelial denuda-
tion. HUVEC monolayers were wounded in vitro, and the presence of
MMP14 and endoglin was detected by immunofluorescence at the
indicated time points. Cells were incubated with a mouse antibody
anti-endoglin (P4A4) or a rabbit antibody anti-MMP14, followed by a
secondary anti-mouse IgG coupled to Alexa 488 (green staining) or a
secondary anti-rabbit IgG coupled to Alexa 647 (red staining).
(a) Single staining and merge images plus DAPI (nuclear staining in
blue) are shown at the indicated magnifications (409 and 639). The
arrows indicate sites where MMP14 and endoglin co-localize (yellow
color). A magnification (639) of the merge images (area within the
square) is shown in the right column. (b) Using merge images (639),
measurements of endoglin (green) and MMP14 (red) along 30-lm
length longitudinal sections of representative membrane areas (indi-
cated by arrows) of each condition were carried out. Fluorescence
intensities were measured and represented in histograms using Image
J software tool. Densitometry profiles of the region of interest (ROI)
and distributions of both signals at distinct time points (0, 4, and 6 h)
are shown. c Representative merge images showing the co-localiza-
tion of MMP14 and endoglin (area within the two white lines) in
cytofluorograms. This scatter plot shows an increased co-localization
area/area foreground (or total fluorescence area) upon endothelial
wounding. d Quantification (percentage) of MMP14 and endoglin co-
localization obtained from the cytofluorograms. **p\ 0.01;
***p\ 0.001 with respect to time 0 h. This is a representative
experiment of ten different ones
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1 lg/well of pGL2-luc basic promoter, pGL2-luc-pMT1-
1544, pGL2-luc-pMT1-800 or pGL2-luc-pMT1-300 and
Mock or pCIneo-KLF6 expression vector [34] for each
condition. Forty-eight hours after transfection, cell lysates
were analyzed using dual-luciferase reporter assay system
(Promega) in a GloMax multidetection system luminome-
ter (Promega). Transfection efficiency was normalized to
b-galactosidase luciferase activity.
Chromatin inmunoprecipitation assays (ChIP)
ChIP experiments were performed with ChIP-IT Express
Enzymatic kit (#53009; Active Motif) in HUVECs, as
described by Garrido et al. [34]. Briefly, aliquots of the
final sheared chromatin were used as ‘‘input chromatin’’
and the rest was incubated with protein G magnetic beads
and 10 lg of rabbit polyclonal antibody antihuman KLF6
(#R-173; sc-7158, Santa Cruz Biotechnology), rabbit
polyclonal antibody anti-histone H3K4me2 (#39141;
Active Motif) or control rabbit IgG (#sc-2027; Santa Cruz
Biotechnology). Protein G magnetic beads bound to the
immune complexes were pelleted, washed and eluted.
Then, cross-linking was reversed and samples were incu-
bated with proteinase K and precipitated prior to resus-
pension in TE buffer. Binding of KLF6 was analyzed by
PCR using primer pairs of four main KLF6-sites rich
regions in the MMP14 promoter sequence. The first region
encompasses from -1142 to -857 (285-bp), the second
one from -783 to -569 (214-bp), the third one from -107
to ?72 (179-bp) and the fourth one from -7 to ? 233
(240 bp). Sequences of primer pairs were: first region, Fwd
50-AGACTTCTATTCTTCTGCCA-30 and Rev 50-ATAAA
GCTGACCGTGAGA-30; second region, Fwd 50-CTTTAA
GAATTGCCTCCTTT-30 and Rev 50-CCAACCTTTGTA
GAAAGACA-30; third region, Fwd 50-GGCTAAAACA
ACCACGTC-30 and Rev 50-GTGCCTGTTTGCTCTTC
T-30; and fourth region, Fwd 50-AGGGAACCAGACCCC



































































Fig. 4 Soluble endoglin is
released during wound healing
of endothelial cells. HUVEC
monolayers were wounded
in vitro, culture supernatants
were collected at different
times, and levels of soluble
endoglin (a) and IL6 (b) were
measured by ELISA and
compared to unwounded cells
(control). Concentrations of
soluble endoglin and IL6 are
referred to 5 9 106 cells. Basal
levels of unwounded cells were
substracted from IL6 levels of
cells after wounding at the same
time points. *p\ 0.05;
**p\ 0.01; ***p\ 0.001 with
respect to time 0 h condition
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For negative and positive control PCRs, primers from
ChIP-IT control human kit (#53010; Active Motif) were
used.
Statistics
Data were subjected to statistical analysis, and the results
are shown as mean ± SD. Differences in mean values were
analyzed using Student’s t test. In figures, statistically
significant values are marked with asterisks (*p\ 0.05;
**p\ 0.01; ***p\ 0.005; ns not significant).
Results
MMP14 and endoglin protein expression increases
during endothelial denudation
We have previously demonstrated that following endothe-
lial injury, KLF6 expression increases and translocates into
the nucleus to specifically enhance the transcriptional
activity of membrane-bound endoglin [35]. Because
MMP14 can target membrane endoglin to release soluble
endoglin [25, 26], we wondered whether MMP-14
expression was also modulated during endothelial wound
healing. After denudation injury experiments performed in
human umbilical vein endothelial cells (HUVECs)
(Fig. 1a), MMP14 and endoglin expression was upregu-
lated at mRNA (Fig. 1b) and cell surface protein (Fig. 2a,
b) levels during the central hours (4–6 h) of the healing
process. As expected, KLF6, a primary response gene to
injury, was upregulated at early stages (2 h; Fig. 1c) of the
wound healing process, an interval that is compatible with
its transcriptional involvement in the subsequent increased
expression of endoglin [35]. Interestingly, suppression of
KLF6 in HUVECs (Fig. 1d) markedly inhibited the injury-
induced expression of MMP14 and endoglin at mRNA
(Fig. 1e, f) and protein (Fig. 2c, d) levels. The upregulation
of MMP14 suggests an active role for its catalytic activity
during the wound healing process. Indeed, using a fluoro-
genic peptide as a substrate, the proteolytic activity of
MMP14 was steadily increased during the endothelial
repair process (Fig. 2e, f). Among others, the proteolytic
activity of MMP14 may contribute to degrade extracellular
matrix proteins, as a typical collagenase that, in turn, could
facilitate the associated endothelial cell migration during
the wound healing process [25, 41, 42]. Accordingly, we
found that suppression of MMP14 leads to a significantly
decreased rate of wound closure in HUVEC monolayers
upon denudation (Supplementary Fig. 1a–d).
Endothelial injury induces co-localization
of MMP14 and endoglin and the release of soluble
endoglin
The parallel increase in MMP14 and endoglin protein
levels, as well as the enhanced MMP14 proteolytic activity
observed during the wound healing process, prompted us to
test whether MMP14 could target membrane endoglin to
release its soluble form. Supporting this hypothesis, co-
localization of MMP14 and endoglin in the plasma mem-
brane of HUVECs under basal conditions and after 4 and
6 h of denudation was observed by confocal microscopy
(Fig. 3a). In agreement with Fig. 2, an increased expres-
sion of both proteins was detected at 4–6 h after wounding,
a time period associated with an active cellular migration.
Immunostaining of MMP14 was observed in the membrane
of those cells close to the edge of the wound. Some of these
cells showed a clear co-localization of MMP14 and endo-
glin, as depicted in the merged images (yellow staining).
Control staining in the absence of primary antibodies did
not show any positive signal (data not shown), excluding a
potential trapping of the immunofluorescent secondary
antibodies, especially by the cell monolayer in the front of
advance. In addition, a parallel distribution of MMP14 and
bFig. 5 KLF6 regulates MMP14 expression. Klf6?/- heterozygous
mice express lower levels of MMP14 after endothelial injury.
a Immunohistochemical staining of MMP14 in mouse femoral artery
after endothelial injury (4 weeks) compared to uninjured samples
from Klf6?/- heterozygous and Klf6?/?WT mice. Pictures were
taken at 925 magnification. In WT animals, MMP14 expression is
upregulated (black arrows) in neointima and tunica media of femoral
arteries after endothelial injury and this upregulation was less
pronounced in Klf6 heterozygous mice. b Histograms representing
the MMP14 media expression samples (n = 5 for each condition) of
femoral arteries after endothelial injury comparing WT and Klf6
heterozygous mice. Measurements of whole vessels (upper his-
togram) and endothelium/neointima (bottom histogram) were nor-
malized taking into account the width of vessels or neointima,
respectively (*p\ 0.05 with respect to control condition). NI,
neointima; TM, tunica media. c–e Overexpresssion of KLF6 increases
MMP14 mRNA expression and soluble endoglin release in cultured
cells. HEK293T cells were transfected with expression vectors
encoding KLF6 (pciNeo KLF6) or endoglin (Eng) and an empty
vector (Mock), as indicated. Quantification by qRT-PCR of ectopic
KLF6 (c) and endogenous MMP14 (d) transcript levels. Levels of
soluble endoglin released to the medium were measured by ELISA
(e). f–i Overexpresssion of KLF6 increases MMP14 mRNA expres-
sion and soluble endoglin release in HUVECs. HUVECs were
nucleofected with an expression vector encoding KLF6 (pciNeo
KLF6) or an empty vector (Mock), as indicated. Quantification by
qRT-PCR of KLF6 (f) and endogenous endoglin (g) and MMP14
(h) transcript levels. Levels of soluble endoglin released to the
medium from HUVECs subjected to endothelial denudation for 6 h
were measured by ELISA (i). j KLF6 suppression was carried out in
HUVECs by nucleofection with siRNA specific for KLF6 (siKLF6),
using Scrambled siRNA (siScrambled) as a control. Nucleofected
HUVECs were wounded in vitro and supernatants were collected at
different times. Soluble endoglin levels were measured by ELISA, as
described in Materials and Methods. In c–i, values were normalized to
mock or untreated cells at time 0 h. *p\ 0.05 as indicated
Angiogenesis (2016) 19:155–171 163
123
endoglin was found along a drawing line above the edge of
the wound after 4 and 6 h of injury, whereas an irregular
distribution was found in the resting condition of the
confluent HUVEC monolayer (Fig. 3b). A scatter plot
(cytofluorogram) analysis of both fluorescent signals also
showed an increased co-localization area/area foreground
(or total fluorescence area) at 4 h and 6 h after wounding
with respect to time 0 (Fig. 3c, d). Moreover, suppression
of KLF6 with siRNA led to a decrease in the MMP14 and
endoglin co-localization rate after wounding associated
with a marked decrease in their basal expression (Supple-
mentary Fig. 2). Further support for the association
between endoglin and MMP14 was provided by co-im-
munoprecipitation studies (Supplementary Fig. 3). Thus,
endoglin was detected by Western blot analysis after
immunoprecipitation with anti-MMP14 antibodies in
HUVECs, and this endoglin signal was enhanced at 6 h
after wounding or upon ectopic expression of KLF6
(Supplementary Fig. 3a). By contrast, the intensity of the
MMP14-associated endoglin band was decreased upon
silencing of KLF6 with siRNA (Supplementary Fig. 3b).
Next, we assessed whether the co-localization of
MMP14 and endoglin was associated with an increased
shedding of soluble endoglin. Indeed, levels of soluble
endoglin were markedly increased in the culture medium of
HUVEC monolayers at different time points after
denudation, showing the maximum endoglin shedding at
8 h after wounding (Fig. 4a). Furthermore, suppression of
MMP14 in HUVEC monolayers led to significantly
decreased levels of soluble endoglin at 6 and 8 h after
wounding compared to controls (Supplementary Fig. 1e, f).
In agreement with a recent report [34], IL6 levels were also
induced upon endothelial denudation, showing a similar
kinetics as soluble endoglin (Fig. 4b).
KLF6 upregulates expression of MMP14
after endothelial injury
KLF6 is a common transcription factor that is upregulated
at the beginning of the activation phase in the endothelial
injury model, as shown in Fig. 1c, in agreement with pre-
vious reports [34, 35]. This kinetics induction of KLF6 is
compatible with the subsequent increase in MMP14 protein
levels. To assess the effect of Klf6 suppression in vivo,
MMP14 expression was studied in heterozygous Klf6?/-
and wild-type mice, using a model of wire-induced
endothelial injury. Four weeks after removal of the tunica
intima (endothelial layer) from the hindlimb femoral
artery, the presence of MMP14 was examined by
immunohistochemistry (Fig. 5a, b; Supplementary Fig. 4).
In uninjured vessels from wild-type and KLF6 heterozy-
gous littermates, the presence of MMP14 was almost
undetectable. By contrast, expression of MMP14 was
clearly increased after injury compared with uninjured
femoral arteries of wild-type mice. On vascular injury,
MMP14 was mainly localized in ECs of the hyperplasic
neointima and in the thicker tunica media, composed
mainly by vascular smooth muscle cells (vSMCs) (Fig. 5a).
Interestingly, MMP14 staining in injured vessels of
Klf6?/- mice was significantly decreased relative to control
wild-type littermates (Fig. 5a, b). These results suggest that
KLF6 regulates the expression of MMP14.
MMP14 gene is a transcriptional target of KLF6
To assess whether MMP14 is a transcriptional target of
KLF6, transient transfection experiments were performed
in HEK293T cells (Fig. 5c, d). Ectopic expression of KLF6
led to a clear increase in the levels of endogenous MMP14
transcripts, as quantified by qRT-PCR (Fig. 5d). Also, the
simultaneous overexpression of KLF6 and full length
endoglin was associated with an increase in the levels of
soluble endoglin (Fig. 5e). Furthermore, overexpression of
KLF6 in HUVECs increased the levels of endogenous
endoglin and MMP14 transcripts (Fig. 5f–h), as well as the
amount of soluble endoglin under basal conditions and
after endothelial denudation for 6 h (Fig. 5i). By contrast,
suppression of KLF6 in HUVECs (Fig. 1d) decreased the
levels of soluble endoglin induced during the wound
healing process (Fig. 5j). These results suggest that the
upregulated MMP14 proteolytically targets membrane
endoglin releasing its soluble form to the culture media.
To analyze whether the MMP14 gene promoter contains
putative binding motifs for KLF6, an in silico analysis of
the proximal 50-MMP14 promoter region with Genomatix
MatInspector software was carried out (Fig. 6). All pro-
teins of the KLF family are characterized by a highly
conserved DNA binding domain, which preferentially
recognizes sequences designated as Sp1 sites, i.e., ‘‘GC-
box’’ or ‘‘CACCC elements’’ of diverse target genes [32].
We found several GC-rich domains along the -1444/?235
fragment of the MMP14 promoter (Fig. 6), and consensus
motifs for KLF6 were identified at positions -1067,
-1048, -718, -635, -86, -65, ?83, ?152 and ?175
(Fig. 6b, c). Next, the physical interaction between KLF6
and the putative KLF6 binding motifs on the MMP14
promoter was examined by chromatin immunoprecipita-
tion. HUVEC monolayers were subjected to endothelial
denudation, and chromatin immunoprecipitation experi-
ments were assayed using an anti-KLF6 antibody, both in
control situation and after 3 h of endothelial denudation.
KLF6-immunoprecipitated chromatin was subjected to
polymerase chain reaction using different couples of pri-
mers, encompassing the four clusters of KLF6 motifs
present in the MMP14 promoter sequence. As shown in
Fig. 7a, KLF6 binding to MMP14 promoter was detected
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in the four amplified fragments (-1142/-857, -783/-569,
-107/?72 and -7/?233) under basal conditions. More-
over, on endothelial wounding, the binding of KLF6 to
MMP14 promoter was enhanced, as shown in the corre-
sponding densitometric analysis (Fig. 7a). These results
indicate that at least one KLF6 motif within each cluster is
bound to the MMP14 promoter. To study the functional
effect of this interaction, transcriptional experiments using
MMP14 promoter (pMT1) constructs were performed.
Transient co-transfections in HEK293T cells with three
different luciferase-pMT1 deletion constructs, all of them
including putative binding sites for KLF6 (-1544/?247;
-800/?247; and -300/?247), showed a marked activa-
tion (*8–14-fold) upon KLF6 overexpression (Fig. 7b).
The highest stimulation (14-fold) was obtained with the
longest construct (-1544/?247), which contains all the
identified consensus KLF6 motifs. These results demon-
strate that KLF6 is able to functionally interact with the
proximal -1544/?247 fragment of the MMP14 promoter,
stimulating its transcriptional activity.
Discussion
An abnormal process of vascular remodeling may lead to
pathological vascular lesions. Therefore, identification of
molecular mediators implicated in the response to vascular












 -884 GTCTCCCTTTCTCACGGTCAGCTTTATCCTGCCCTCTCCCTTCCCTACATACCTCCACCT 
 -824 TTTGTTCTGAGTCCAGTAAGTCCCTAAAGGAGATTATAACTCTTTAAGAATTGCCTCCTT
 -764 TTTCAGTGTAGAGGTGGAACTAAACCCCAGAGTCCCAACTCCCAATcccttcttttacaa




 -464 GCCCAGAAGATAACCCCCTATTAGTAAACTGGCCCCTTCTCCCTCTGCAGGTCTCATGGG 
 -404 CATGGAAGAAGACCCCACCACCATCCCACACTCTGAGCTCCTCGTTGCCCCTAGCCACAT 
 -344 AGCCCCCAATAATTCCCACCCTGAGGTGAGACAAATGCTGAATACCAGAGGAATCAAGCC 
 -284 ACTCAGAATATGCTTATAGGGACAAAGTCTCCCACATCCCGTCCCCTGGATCCCCCTACA 







 +197 GAGCCCACACTGCCCGGCTGACCCGGTGGTCTCGGACCATGTCTCCCGCC 
b 








Putative KLF6/Sp1 binding motifs
-1577 +197
+1
Fig. 6 In silico analysis of
putative KLF6 binding motifs in
the MMP14 promoter. a GC-
rich domains in the MMP14
promoter fragment -1544/
?247. The percentage of GC
bases along the promoter is
shown. Several GC-boxes that
recruit members of the Sp1/KLF
transcription factors family
were identified. b Putative
transcription factor binding
motifs for KLF6 (bold letters) in
the plus (capitals) and negative




The translation initiation codon
is marked in red. The
numbering of the nucleotides is
referred to the predicted
transcription initiation site (?1)
identified by the Genomatix
MatInspector software.
c Potential KLF6 (red) and Sp1
(blue) binding sites on the
MMP14 gene promoter as
identified by the Genomatix
MatInspector software
Angiogenesis (2016) 19:155–171 165
123
vascular repair. Accumulated evidence in recent years
implicates the transcription factor KLF6 in orchestrating the
gene expression response of ECs to vascular injury [31, 33].
Endothelial expression of KLF6 is upregulated upon
vascular injury and is responsible for the transcriptional
activation of several genes involved in vascular remod-
eling, including endoglin, ALK1, urokinase plasminogen
activator, collagen a1(I), TGF-b1 and TGF-b receptor type I
[34, 35, 38]. Here, we provide evidence supporting the
inclusion of MMP14 in the list of vascular genes regulated by
KLF6. Using in vitro and in vivo models, we show that
MMP14 is upregulated at the surface of ECs after vascular
injury. Following endothelial wound healing, we found a
temporal relationship between MMP14 and KLF6 transcript
a
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upregulation that is compatible with a transcriptional
involvement of KLF6 in MMP14 gene expression regula-
tion. Supporting this observation, MMP14 protein levels are
much lower in injured femoral arteries of Klf6?/- mice than
those of wild-type animals. Also, suppression of KLF6 in
cultured ECs decreases MMP14 expression and the subse-
quent release of soluble endoglin. Furthermore, ectopic
expression of KLF6 is able to markedly transactivate the
MMP14 gene promoter construct specifically designed and
generated for this purpose. Previous reports have postulated
that E2F and Ets families of transcription factors play a role
in cancer through regulation of MMP14 gene promoter
activity [43, 44]. In addition, transcription factors Egr-1, Sp1
and Sp3 are involved in the regulated expression of MMP14
in endothelial cells driven by hemodynamic forces and
extracellular matrix contacts [45–47]. To our knowledge,
this is the first study that analyzes the transcriptional activity
of an MMP14 gene promoter construct in response to
endothelial injury. Our results prompted us to explore the
potential regulation by KLF6 of the MMP14 gene. An in
silico analysis of the proximal MMP14 promoter sequence
revealed the presence of nine putative consensus binding
sites for KLF6 along the -1544/?247 pMT1 fragment. The
motifs are located at positions -1067, -1048, -718, -635,
-86, -65, ?83, ?152 and ?175. By chromatin immuno-
precipitation, we demonstrate not only that KLF6 binds to
four different KLF6 clusters (-1142/-857, -783/-569,
-107/?72 and -7/?233) of the MMP14 promoter, but we
also show that this binding is increased on endothelial injury
in vitro. This finding agrees with the functional effect of
KLF6 in transcriptional experiments using several MMP14
promoter constructs. Indeed, all constructs, including puta-
tive binding sites for KLF6 (-1544/?247; -800/?247; and
-300/?247), showed a marked activation upon ectopic
expression of KLF6. Together, these results demonstrate that
KLF6 is able to functionally interact with the MMP14 pro-
moter, stimulating its transcriptional activity. Importantly,
many of the KLF6 motifs in the proximal MMP14 promoter
are located at GC-rich regions where they overlap, or are
surrounded by, consensus binding sites for the transcription
factor Sp1 (Fig. 6). The physical proximity between KLF6
and Sp1 motifs suggests a synergistic collaboration of both
transcription factors in the transcriptional machinery com-
plex of MMP14. Supporting this interpretation, we have
previously demonstrated the direct physical interaction and
functional cooperation between Sp1 and KLF6 on endoglin
and ALK1 gene promoters, in response to vascular injury
[34, 35, 48].
Here, we report for the first time that endothelial
denudation in vitro leads to an increase in soluble endoglin
levels. Interestingly, MMP14 co-localizes with and targets
membrane-bound endoglin to proteolytically release sol-
uble endoglin. Overall, the functional link between
MMP14 and endoglin in their parallel gene expression in
response to endothelial damage supports their coordinated
involvement in the molecular events triggered by a vas-
cular injury to recover the endothelial homeostasis. While
the role of MMP14 in vascular remodeling and the cellular
processes involved has been previously described [17, 49–51],
little is known about the role of soluble endoglin in this
specific setting. Circulating levels of soluble endoglin are
elevated in preeclampsia, hypercholesterolemia, diabetes,
atherosclerosis, severe pulmonary arterial hypertension,
acute myocardial infarction and some types of solid can-
cers [27–29, 52–54]. Of note, many of these pathologies
are associated with cardiovascular damage. At variance
with the pro-angiogenic role of membrane-bound endoglin,
soluble endoglin displays an anti-angiogenic activity
[25, 27, 30], which has been postulated as a pathogenic
contributor in preeclampsia [27]. In the context of cardio-
vascular repair after injury, active angiogenesis and
endothelial cell proliferation are expected to occur in order
to reestablish the proper circulation in the tissues. KLF6, an
upstream trigger of soluble endoglin, is strongly expressed
in ECs of highly vascularized tissues such as placenta and
lung, and promotes vascular remodeling [31]. Thus, it is
bFig. 7 KLF6 interacts with MMP14 gene promoter and regulates its
activity. a KLF6 interacts with MMP14 promoter in HUVECs. In
silico analysis revealed the presence of potential KLF6-binding sites
(black ovals) within GC-rich domains on MMP14 gene promoter
using Genomatix MatInspector software (scheme in upper panel).
Chromatin immunoprecipitation (ChIP) experiments of KLF6 over
the 50-proximal MMP14 promoter were carried out in HUVECs
comparing control condition and after 3 h of wound healing (middle
panel). The chromatin was digested obtaining a 150–300-bp frag-
ments-enrichment. Immunoprecipitation was carried out with anti-
KLF6, anti-H3K4 (positive control) and non-immune (IgG) antibod-
ies. PCRs were done with primers to detect four regions containing
putative KLF6-sites in the promoter region of MMP14, using the total
lysate as an input of the sample. KLF6 binding to the different
pMMP14 regions from the ChIP experiment was measured by
densitometry of the individual bands, and values of the (KLF6-IgG)/
Input ratios were represented (bottom panel). Normalized ratios in
basal conditions (C) and 3 h after the endothelial injury (I) are shown.
b KLF6 transactivates the MMP14 promoter. Left 50-deleted construct
series of the MMP14 promoter cloned into pGL2-luc. The size of each
construct compared with the size of the whole promoter construct is
shown in the scheme. The drawing is not to scale. Right HEK293T
was co-transfected with a luciferase reporter driven by different
MMP14 promoter constructs in pGL2-luc (-1544/?247 pMT1;
-800/?247 pMT1; and -300/?247 pMT1) which include different
putative binding GC-rich motifs for KLF6, and the expression vector
pCIneo-KLF6. The pGL2-Luc empty vector (Ø) was used as a
negative control. Overexpression of KLF6 upregulates between 8 and
14 times the activities of the MMP14 promoter constructs. The
relative promoter activity under basal conditions is indicated in the
corresponding bars, and the actual values of luciferase activity are
shown in parenthesis. Transfection efficiency was corrected by
relating luciferase activity to b-galactosidase activity. Results are
expressed as a fold induction with respect to the basal activity of the
corresponding constructs (**p\ 0.01; ***p\ 0.001)
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intriguing the role of the anti-angiogenic activity associated
with soluble endoglin during the vascular repair process.
Probably, the release of soluble endoglin constitutes an
early response to vascular damage that halts angiogenesis,
followed by a second phase involving the upregulation of
membrane-bound endoglin and active angiogenesis [6, 35,
55]. In this regard, the release of soluble endoglin may
have important consequences at the cellular level as it is
associated with the decrease in the surface endoglin, which
may lead to the downregulation of the ALK1/endoglin-
dependent signaling pathway, a route that in ECs promotes
angiogenesis [6, 36]. Further studies are necessary to elu-
cidate the exact role of soluble endoglin, and the associated
downregulation of membrane-bound endoglin, on the vas-
cular repair process.
Although we have focused our MMP14 studies on its
endothelial expression and function, MMP14 can be
expressed by other cell types including vSMCs [49, 50]. This
is in agreement with the expression of MMP14 in the layer of
vSMCs surrounding the tunica intima after endothelial
denudation of the femoral artery as seen in Fig. 5a. Of note,
vSMCs can also express the MMP14 substrate endoglin in
pathological vessels [56]. At variance with ECs, vSMCs are
not directly injured in this animal model. Thus, a cross-talk
between endothelial and smooth muscle cell layers appears
necessary to explain the upregulated expression of MMP14
in vSMCs on vascular injury. In this line, an increase in IL-6
along the in vitro wounding process of ECs has been reported
[34]. Moreover, KLF6 regulates the transcriptional activity
of IL6 gene, suggesting that IL6 is a putative candidate to
contribute to the paracrine effect on vSMCs surrounding the
endothelium [34]. Supporting the involvement of IL6 in the
vascular repair process is the finding that IL-6 KO mice take
three times longer to heal than wild-type animals [57]. Thus,
it can be postulated that the release of soluble factors, such as
IL-6, from the injured endothelium would serve to expand
the repair signal from the inner to the more distant layers of
the vessel. This coordinated cross-talk between vSMCs and
ECs [50] and the upregulated expression of MMP14 in
vSMCs upon vascular damage are in agreement with the
critical role that vSMCs play during pathologic vascular
remodeling. Thus, VSMCs embedded within the collagen-
Fig. 8 Hypothetical model of KLF6 regulation during vascular
injury. Upon vascular injury, KLF6 translocates from the cytoplasm
to the nucleus and activates endothelial genes such as endoglin [35],
ALK1 [34], IL6 [34] and MMP14 (this report). Endoglin and MMP14
co-localize at the cell surface. Then, MMP14 triggers the release of
soluble endoglin. Soluble proteins such as IL6, endoglin and TGF-b
are potential players in the cross-talk between ECs and vSMCs during
wound healing
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rich matrix of the artery wall mobilize and activate MMP14
to degrade and infiltrate 3D barriers of interstitial collagen,
including the arterial wall. In fact, genetic deletion of
MMP14 affords mice with a protected status against neoin-
timal hyperplasia and lumen narrowing in vivo [49].
In summary, our studies demonstrate for the first time a
functional relationship between the transcription factor
KLF6 and MMP14 expression (Fig. 8). Also, after vascular
injury, KLF6 is responsible for the increased expression of
membrane endoglin in endothelial cells and the subsequent
MMP14-dependent release of soluble endoglin. The levels
of IL6, a proangiogenic and proinflamatory cytokine, are
also increased, as a consequence of KLF6 activation. Both
IL6 and soluble endoglin could contribute to the cross-talk
between ECs and vSMCs, which is involved in the mech-
anism of wound healing. Overall, these results suggest that
KLF6 is a master regulator during vascular injury, repair
and migration, and can play a role in physiological and
pathological processes of the blood vessels.
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